It also looks like the company has created yet another believer. Recently, it successfully brought MedImmune, the biologics arm of pharma giant AstraZeneca, into the fold. MedImmune acquired the rights to INO-3112, which is in early clinical studies as a treatment against cancers of the cervix, head, and neck. The partnership announcement sent the stock soaring, and has the potential to be a financial bonanza for Inovio.
Please be so kind as to note that "the Fool" I reference is the Motley Fool with the usual drivel.
Dr. Kim's secret sauce at INO that has now hooked an even more formidable opponent than J&J in AstraZeneca IMHO is the venerable technology of electroporation. Mild electric current applied to the skin allows introduction of drugs [and pathogens and...] to the lymph system. Dr. Kim, a respectable researcher but a far superior promoter, claims he has a far superior electroporater somehow that will revive prospects for a horde of failed drugs.
I would not bet a nickel against Dr. Kim succeeding - I have seen far more novel and unlikely ideas succeed gloriously - but I prefer the powerful evidence accumulating for ADXS' technical excellence.
Best, Terry